148 related articles for article (PubMed ID: 36994539)
21. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer.
Shimokawa T; Shibuya M; Kitamura K; Hosomi Y; Hibino S; Ota T; Iguchi M; Okamura T; Gemma A
Int J Clin Oncol; 2009 Feb; 14(1):63-9. PubMed ID: 19225927
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
[TBL] [Abstract][Full Text] [Related]
23. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
Peng Y; Wang Y; Li J; Hao X; Hu X
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy.
Asai N; Ohkuni Y; Matsunuma R; Nakashima K; Iwasaki T; Kaneko N
J Cancer Res Ther; 2012; 8(2):266-71. PubMed ID: 22842373
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.
Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y
Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449
[TBL] [Abstract][Full Text] [Related]
26. Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin.
Imai H; Kaira K; Mori K; Watase N; Hisada T; Yamada M; Minato K
J Cancer Res Ther; 2020; 16(4):764-770. PubMed ID: 32930116
[TBL] [Abstract][Full Text] [Related]
27. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
[TBL] [Abstract][Full Text] [Related]
28. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
Igawa S; Yamamoto N; Ueda S; Ono A; Nakamura Y; Tsuya A; Murakami H; Endo M; Takahashi T
J Thorac Oncol; 2007 Aug; 2(8):741-4. PubMed ID: 17762341
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
[TBL] [Abstract][Full Text] [Related]
31. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
Miura Y; Kaira K; Sakurai R; Sunaga N; Saito R; Hisada T; Yamada M
Lung Cancer; 2018 Jan; 115():42-48. PubMed ID: 29290260
[TBL] [Abstract][Full Text] [Related]
32. Severe interstitial lung disease associated with amrubicin treatment.
Yoh K; Kenmotsu H; Yamaguchi Y; Kubota K; Ohmatsu H; Goto K; Niho S; Ohe Y; Saijo N; Nishiwaki Y
J Thorac Oncol; 2010 Sep; 5(9):1435-8. PubMed ID: 20683210
[TBL] [Abstract][Full Text] [Related]
33. Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
Sato Y; Iihara H; Kinomura M; Hirose C; Fujii H; Endo J; Yanase K; Kaito D; Sasaki Y; Gomyo T; Sakai C; Iwai M; Tsuboi Y; Ishihara T; Kobayashi R; Ohno Y; Suzuki A
Anticancer Res; 2021 Mar; 41(3):1615-1620. PubMed ID: 33788757
[TBL] [Abstract][Full Text] [Related]
34. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
[TBL] [Abstract][Full Text] [Related]
37. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
[TBL] [Abstract][Full Text] [Related]
38. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
